Six pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc.’s (PATH) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
GW Pharmaceuticals PLC Sponsored ADR (GWPH) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Paratek Pharmaceuticals Inc (PRTK) earns an A this week, jumping up from last week’s grade of B. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
Cardiome Pharma’s (CRME) ratings are looking better this week, moving up to a B from last week’s C. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.
The rating of AbbVie, Inc. (ABBV) moves up this week, rising from a C to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
